Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 September 2020Website:
http://www.tangotx.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
TNGX Latest News
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
STOCKHOLM , May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts. TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor, for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers, and has been developed by Tango from the preclinical USP1 program licensed from Medivir in 2020.
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
The average of price targets set by Wall Street analysts indicates a potential upside of 110.5% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. The company recently raised capital to fund all operations well into 2027, and a beneficial owner/director just added just over $2.4 million of new shares to their stake. An updated analysis on Tango Therapeutics follows in the paragraphs below.
The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.
Tango Therapeutics is a clinical-stage biotech. The company has five programs in its pipeline that are focused on fighting various cancers.
Tango Therapeutics, Inc. (TNGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Tango said it has $310.7 million in cash, enough to fund operations into 2026. The company has several early-stage trials.
What type of business is Tango Therapeutics?
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
What sector is Tango Therapeutics in?
Tango Therapeutics is in the Healthcare sector
What industry is Tango Therapeutics in?
Tango Therapeutics is in the Biotechnology industry
What country is Tango Therapeutics from?
Tango Therapeutics is headquartered in United States
When did Tango Therapeutics go public?
Tango Therapeutics initial public offering (IPO) was on 03 September 2020
What is Tango Therapeutics website?
https://www.tangotx.com
Is Tango Therapeutics in the S&P 500?
No, Tango Therapeutics is not included in the S&P 500 index
Is Tango Therapeutics in the NASDAQ 100?
No, Tango Therapeutics is not included in the NASDAQ 100 index
Is Tango Therapeutics in the Dow Jones?
No, Tango Therapeutics is not included in the Dow Jones index
When was Tango Therapeutics the previous earnings report?
No data
When does Tango Therapeutics earnings report?
The next expected earnings date for Tango Therapeutics is 08 November 2024